IN2015DN04209A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN04209A IN2015DN04209A IN4209DEN2015A IN2015DN04209A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A IN 4209DEN2015 A IN4209DEN2015 A IN 4209DEN2015A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A
- Authority
- IN
- India
- Prior art keywords
- methods
- igf1r
- cancers
- insulin
- constituent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The present invention relates generally to methods and compositions for the treatment of cancers expressing the type 1 insulin like growth factor receptor (IGF1R) or a constituent of an IGF1R signaling pathway in particular melanoma using the microRNA miR 7 5p. Also provided are methods for increasing the sensitivity of such cancers to therapeutic agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012904570A AU2012904570A0 (en) | 2012-10-18 | Cancer therapy using miRNAs | |
PCT/AU2013/001208 WO2014059484A1 (en) | 2012-10-18 | 2013-10-18 | CANCER THERAPY USING miRNAs |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN04209A true IN2015DN04209A (en) | 2015-10-16 |
Family
ID=50487345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4209DEN2015 IN2015DN04209A (en) | 2012-10-18 | 2013-10-18 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9795626B2 (en) |
EP (1) | EP2908830A4 (en) |
CN (1) | CN104994861B (en) |
IN (1) | IN2015DN04209A (en) |
WO (1) | WO2014059484A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3800256A1 (en) * | 2012-11-06 | 2021-04-07 | InteRNA Technologies B.V. | Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway |
ES2596711B1 (en) * | 2015-07-09 | 2017-10-27 | Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Paz | Determination of the methylation and levels of a miRNA in response to a platinum-based antitumor compound |
CN106367419A (en) * | 2016-10-10 | 2017-02-01 | 徐州医科大学 | Antisense oligonucleotide with neuroprotective effect, medicine composition and application thereof |
EP3571200B8 (en) | 2017-01-17 | 2022-08-03 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2018226802A1 (en) * | 2017-06-06 | 2018-12-13 | The Johns Hopkins University | Induction of synthetic lethality with epigenetic therapy |
AU2018344761A1 (en) * | 2017-10-03 | 2020-05-07 | GeneSeq Pty Ltd | A method of diagnosis, staging and monitoring of melanoma using microrna gene expression |
CN109536497A (en) * | 2018-11-28 | 2019-03-29 | 同济大学 | The application of schistosoma japonicum infection and its component in human tumor prevention and treatment |
US11750706B1 (en) * | 2020-03-26 | 2023-09-05 | Amazon Technologies, Inc. | Data transmission time management |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2557411T3 (en) | 2006-01-05 | 2016-01-25 | The Ohio State University Research Foundation | Methods and compositions based on microRNA for the diagnosis and treatment of solid cancers |
JP2013511559A (en) * | 2009-11-24 | 2013-04-04 | ザ ユニバーシティ オブ ウェスタン オーストラリア | Modulation of epidermal growth factor receptor ligand |
-
2013
- 2013-10-18 CN CN201380065503.0A patent/CN104994861B/en not_active Expired - Fee Related
- 2013-10-18 EP EP13847499.4A patent/EP2908830A4/en not_active Withdrawn
- 2013-10-18 WO PCT/AU2013/001208 patent/WO2014059484A1/en active Application Filing
- 2013-10-18 IN IN4209DEN2015 patent/IN2015DN04209A/en unknown
- 2013-10-18 US US14/436,638 patent/US9795626B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014059484A1 (en) | 2014-04-24 |
US20150366895A1 (en) | 2015-12-24 |
EP2908830A1 (en) | 2015-08-26 |
CN104994861B (en) | 2019-10-11 |
US9795626B2 (en) | 2017-10-24 |
EP2908830A4 (en) | 2016-11-30 |
CN104994861A (en) | 2015-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN04209A (en) | ||
PH12015501737A1 (en) | Androgen receptor modulators and uses thereof | |
PH12015500825A1 (en) | Substituted benzene compounds | |
TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
MX2013002975A (en) | Estrogen receptor modulators and uses thereof. | |
PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
MX2013011922A (en) | Substituted benzene compounds. | |
GB201106743D0 (en) | Novel compounds | |
IN2015DN02032A (en) | ||
MX2015007180A (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases. | |
MY185016A (en) | Progenitor cells of mesodermal lineage | |
EP2558124A4 (en) | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization | |
MX2013004061A (en) | Cyclosporin analogs. | |
MX2014010537A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions. | |
MX2013013649A (en) | Quinone compounds for treating ape1 mediated diseases. | |
MX2014010713A (en) | Procaspase 3 activation by combination therapy. | |
IN2015MN00027A (en) | ||
MX2013004062A (en) | Cyclosporin analogs. | |
MX2015005732A (en) | Tricyclic compounds and methods of making and using same. | |
MX2016002930A (en) | Liver x receptor (lxr) modulators. | |
UA117567C2 (en) | Galactagogue compositions based on phosphatidylserine | |
MX2013003859A (en) | Picropodophyllin polymorphs b or c for use in cancer therapy. | |
MX2013008559A (en) | Leptin derivatives. | |
GB201212586D0 (en) | Cancer treatment |